MNKD MannKind Corporation

1.53
-0.01  -1%
Previous Close 1.54
Open 1.53
Price To Book -1.64
Market Cap 287294266
Shares 187,774,030
Volume 1,981,004
Short Ratio
Av. Daily Volume 3,379,411

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 27, 2014.
AFREZZA
Type 1/2 diabetes
Phase 1 trial completion announced June 7, 2018.
Treprostinil Technosphere
Pulmonary Arterial Hypertension (PAH)

Latest News

  1. MannKind to Present at the H.C. Wainwright Global Life Sciences Conference
  2. MannKind Receives $12.5 Million Milestone Payment from United Therapeutics
  3. Analysts Give Positive Recommendations to MannKind in March
  4. MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?
  5. MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?
  6. What Analysts Are Recommending for MannKind and Akebia in March
  7. MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly
  8. These Four Healthcare Stocks Are Making Moves on Wednesday
  9. Edited Transcript of MNKD earnings conference call or presentation 26-Feb-19 2:00pm GMT
  10. MNKD: A Head Start to 2019; Q4 and Annual 2018 Earnings Results
  11. MannKind Corp (MNKD) Q4 2018 Earnings Conference Call Transcript
  12. Here's Why MannKind Rocketed Higher Today
  13. MannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call
  14. MannKind Corporation to Host Earnings Call
  15. Q4 Earnings Outlook For MannKind
  16. The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
  17. MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
  18. MannKind Corporation Participating at Upcoming Conferences
  19. MannKind Corporation to Hold 2018 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2019
  20. Weekly CFO Buys Highlight